Effect of Resveratrol on Insulin Resistance and Inflammatory Mediators in Obese and Type 2 Diabetic Subjects.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Resveratrol (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacodynamics
Most Recent Events
- 18 Dec 2012 Biomarkers information updated
- 17 Dec 2012 Planned End Date changed from 1 Apr 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.
- 17 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.